Search Results - "Stegnar, Mojca"

The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement by Herman, Darja, Peternel, Polona, Stegnar, Mojca, Breskvar, Katja, Dolzan, Vita

“…The degree of interpatient variability in the warfarin dose required to achieve the desired anticoagulant response can only partly be explained by…”
Get more information

High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy by Vene, Nina, Mavri, Alenka, Kosmelj, Katarina, Stegnar, Mojca

“…Atrial fibrillation (AF) is associated with hemostatic abnormalities and increased risk of thrombotic cardiovascular events even during oral anticoagulant…”
Get more information

Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors by Sebestjen, Miran, Keber, Irena, Zegura, Branka, Simcic, Sasa, Bozic, Mojca, Fressart, Martine Migaud, Stegnar, Mojca

“…The effects of cerivastatin and fenofibrate on proteins involved in haemostasis and on markers of inflammation were investigated in otherwise healthy…”
Get more information

Impact of Adipose Tissue on Plasma Plasminogen Activator Inhibitor-1 in Dieting Obese Women by Mavri, Alenka, Stegnar, Mojca, Krebs, Michael, Sentocnik, Jozica T, Geiger, Margarethe, Binder, Bernard R

“…The increased incidence of cardiovascular diseases in obese subjects could be partially attributed to impaired fibrinolysis due to elevated plasma levels of…”
Get full text

The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism by Stegnar, M, Uhrin, P, Peternel, P, Mavri, A, Salobir-Pajnic, B, Stare, J, Binder, B R

“…Impaired fibrinolysis due to increased plasminogen activator inhibitor-1 (PAI-1) is observed in up to 40% of patients with venous thromboembolism and might be…”
Get more information

A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C924) in a patient on warfarin therapy by Herman, Darja, Peternel, Polona, Stegnar, Mojca, Breskvar, Katja, Dolzan, Vita

Get more information

Thrombophilia screening--at the right time, for the right patient, with a good reason by Stegnar, Mojca

“…Thrombophilia can be identified in about half of all patients presenting with venous thromboembolism (VTE). Thrombophilia screening for various indications has…”
Get more information

Hemostasis activation in thrombophilic subjects with or without a history of venous thrombosis by Cuderman, Tjasa Vizintin, Bozic, Mojca, Peternel, Polona, Stegnar, Mojca

“…Thrombophilia is considered to increase the risk of venous thrombosis (VT) due to hemostasis activation. To determine the level of hemostasis activation in…”
Get more information

Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models by Peternel, Luka, Stegnar, Mojca, Drevensek, Gorazd, Budihna, Metka V, Bozic, Mojca, Zega, Anamarija, Stalc, Anton, Cerne, Manica, Urleb, Uros

“…The antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold (LK-732, LK-639 and LK-731) and their amidoxime prodrugs…”
Get more information

Fibrinolytic response to venous occlusion in healthy subjects: relationship to age, gender, body weight, blood lipids and insulin by Stegnar, M, Pentek, M

“…The physiological variability of fibrinolytic response to 20 min upper arm venous occlusion was studied in 191 healthy women and men, 19-80 years old. It was…”
Get more information

Platelet function tests and resistance to antiplatelet therapy by Stegnar, Mojca

“…The clinical efficacy of antiplatelet therapy (aspirin, P2Y12 and glycoprotein IIb/IIIa receptor antagonists) to prevent occlusive arterial events in patients…”
Get full text

3,4-Dihydro-2H-1,4-benzoxazine Derivatives Combining Thrombin Inhibitory and Glycoprotein IIb/IIIa Receptor Antagonistic Activity as a Novel Class of Antithrombotic Compounds with Dual Function by Ilaš, Janez, Jakopin, Žiga, Borštnar, Tina, Stegnar, Mojca, Kikelj, Danijel

“…3,4-Dihydro-2H-1,4-benzoxazine derivatives possessing both thrombin inhibitory and glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonistic activities were…”
Get full text

Survival and event-free survival of patients with peripheral arterial disease undergoing prevention of cardiovascular disease by Blinc, Aleš, Kozak, Matija, Šabovič, Mišo, Božič Mijovski, Mojca, Stegnar, Mojca, Poredoš, Pavel, Kravos, Andrej, Barbič-Žagar, Breda, Stare, Janez, Pohar Perme, Maja

“…Patients with peripheral arterial disease (PAD) are at very high risk for cardiovascular events. How do patients with PAD differ from age- and sex-matched…”
Get more information

Ex vivo neutralization of unfractionated heparin for assessing overall haemostatic potential in patient plasma by Božič-Mijovski, Mojca, Vučnik, Maja, Boc, Vinko, Blinc, Aleš, Stegnar, Mojca

Get full text

Enhanced thrombin generation in women with a history of oral contraception-related venous thrombosis by Anžej Doma, Saša, Vučnik, Maja, Božič Mijovski, Mojca, Peternel, Polona, Stegnar, Mojca

“…Abstract Introduction In women who suffer venous thrombosis (VT) during oral contraceptive (OC) use, a transient risk factor (OC) is removed during the acute…”
Get full text

The effect of pre-analytical variables on light transmittance aggregometry in citrated platelet-rich plasma from healthy subjects by Stegnar, Mojca, Knezevic, Anja, Bozic-Mijovski, Mojca

“…Although light transmittance aggregometry is considered the gold standard for platelet function testing, it is poorly standardized. The effect of several…”
Get more information

C0372 Enhanced thrombin generation in women with history of oral contraception related venous thrombosis by Doma, Saša Anžej, Vučnik, Maja, Mijovski, Mojca Božič, Peternel, Polona, Stegnar, Mojca

Get full text

3,4-Dihydro-2 H -1,4-benzoxazine Derivatives Combining Thrombin Inhibitory and Glycoprotein IIb/IIIa Receptor Antagonistic Activity as a Novel Class of Antithrombotic Compounds with Dual Function by Ilaš, Janez, Jakopin, Žiga, Borštnar, Tina, Stegnar, Mojca, Kikelj, Danijel

Get full text

C0185 Can overall haemostasis potential (OHP) discriminate between patients who will suffer early restenosis after femoropopliteal percutaneous transluminal angioplasty (PTA) from those who will not? by Vučnik, Maja, Boc, Vinko, Blinc, Aleš, Vrtovec, Matjaž, Perme, Rok, Krevel, Barbara, Kozak, Matija, Malovrh, Petra, Eržen, Barbara, Božič-Mijovski, Mojca, Stegnar, Mojca

Get full text

Tissue plasminogen activator release in chronic venous hypertension due to heart failure by Keber, I, Keber, D, Stegnar, M, Vene, N

“…In order to study the effects of chronic venous hypertension due to heart failure on blood fibrinolytic activity, tissue plasminogen activator (t-PA) antigen,…”
Get more information